TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC

被引：0
|
作者：
Forster, M. [1 ]
Krebs, M. [2 ,3 ]
Majem, M. [4 ]
Peguero, J.
Clay, T. [5 ]
Felip, E. [6 ]
Iams, W. [7 ]
Roxburgh, P. [8 ,9 ]
Doger, B. [10 ]
Bajaj, P. [11 ]
Kefas, J. [12 ]
Scott, J. A. [13 ]
Joaquin, A. Barba [4 ]
Mueller, C. [14 ]
Triebel, F. [15 ]
机构：
[1] Univ Coll London Hosp NHS Fdn, Canc Inst, UCL, London, England
[2] Univ Manchester, Div Canc Sci, Manchester, England
[3] Christie NHS Fdn Trust, Manchester, England
[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[5] Hosp St John God Subiaco, Perth, Australia
[6] Vall Hebron Univ Hosp, Barcelona, Spain
[7] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN USA
[8] Univ Glasgow, Inst Canc Sci, Wolfson Wohl Canc Res Ctr, Glasgow, Scotland
[9] Beatson West Scotland Canc Ctr, Glasgow, Scotland
[10] Fdn Jimenez Diaz, Madrid, Spain
[11] Tasman Oncol, Southport, Australia
[12] Univ Coll London Hosp NHS Trust, London, England
[13] Christie NHS Fdn Trust, Manchester, England
[14] Immutep GmbH, Berlin, Germany
[15] Immutep SAS, Orsay, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
LAG-3; NSCLC; PD-1/PD-L1; refractory;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-10
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 50 条
  • [31] Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
    Jung, Hyun Ae
    Park, Sehhoon
    Choi, Yoon-La
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Sun, Jong-Mu
    CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2321 - 2328
  • [32] Detection of Primary Immunotherapy Resistance to PD-1 Checkpoint Inhibitors (PD1CI) in 2nd Line NSCLC
    Aerts, J.
    Smit, E.
    Muller, M.
    Niemeijer, A.
    Oliveira, C.
    Roder, H.
    Roder, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S424 - S424
  • [33] Immune Checkpoint Markers in Superficial Angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and Tumor-Infiltrating Lymphocytes
    Googe, Paul B.
    Flores, Kyle
    Jenkins, Francie
    Merritt, Bradley
    Moschos, Stergios J.
    Grilley-Olson, Juneko E.
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2021, 43 (08) : 556 - 559
  • [34] LAG-3/PD-L1 mAb2 can overcome PD-L1-mediated compensatory upregulation of LAG-3 induced by single-agent checkpoint blockade
    Faroudi, Mustapha
    Kraman, Matthew
    Fosh, Natalie
    Reader, Claire
    Gliddon, Daniel
    Seal, Claire
    Lucas, Christa
    Koers, Alexander
    Wydro, Mateusz
    Morrow, Michelle
    Brewis, Neil
    CANCER RESEARCH, 2019, 79 (13)
  • [35] A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
    Yap, Timothy A.
    LoRusso, Patricia M.
    Wong, Deborah J.
    Hu-Lieskovan, Siwen
    Papadopoulos, Kyriakos P.
    Holz, Josefin-Beate
    Grabowska, Urszula
    Gradinaru, Cristian
    Leung, Kin-Mei
    Marshall, Sylwia
    Reader, Claire S.
    Russell, Roslin
    Sainson, Richard C. A.
    Seal, Claire J.
    Shepherd, Christopher J.
    Germaschewski, Fiona
    Gliddon, Daniel
    Stern, Omer
    Young, Lesley
    Brewis, Neil
    Kayitalire, Louis
    Morrow, Michelle
    CLINICAL CANCER RESEARCH, 2023, 29 (05) : 888 - 898
  • [36] Phase 1/ 2 study of quavonlimab (Qmab) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor
    Deva, Sanjeev
    Mackiewicz, Jacek
    Dalle, Stephane
    Gogas, Helen
    Lugowska, Iwona
    Berrocal, Alfonso
    Menzies, Alexander M.
    Maio, Michele
    Nagrial, Adnan
    Eizmendi, Karmele Mujika
    Grob, Jean-Jacques
    Caglevic, Christian
    Lyle, Megan
    Martin-Liberal, Juan
    Altura, Rachel
    Ren, Yixin
    Khilnani, Anuradha
    Cyrus, Jobin
    Siddiqi, Shabana
    Lotem, Michal
    CANCER RESEARCH, 2022, 82 (12)
  • [37] Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
    Frey, Connor
    Etminan, Mahyar
    ANTIBODIES, 2024, 13 (03)
  • [38] A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
    El Osta, Badi
    Carlisle, Jennifer
    Steuer, Conor
    Pakkala, Suchita
    Leal, Ticiana
    Dhodapkar, Madhav
    Liu, Yuan
    Chen, Zhengjia
    Owonikoko, Taofeek
    Ramalingam, Suresh
    CLINICAL LUNG CANCER, 2022, 23 (07) : E400 - E404
  • [39] Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
    Saleh, Reem
    Toor, Salman M.
    Khalaf, Sarah
    Elkord, Eyad
    VACCINES, 2019, 7 (04)
  • [40] A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1
    Krebs, M.
    Brunsvig, P.
    Helland, A.
    Vinolas, N.
    Aix, S.
    Carcereny, E.
    Domine Gomez, M.
    Trigo Perez, J. M.
    Arriola, E.
    Garcia Campelo, R.
    Spicer, J.
    Thompson, J.
    Ortega Granados, A. L.
    Holt, R.
    Smethurst, D.
    Lorens, J.
    Shoaib, M.
    Siddiqui, A.
    Schoelermann, J.
    Lorens, K.
    Schmidt, E.
    Chisamore, M. J.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S388 - S388
12345